Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.51 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240205 | 0.78 | CHRM2 (0.59) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL1177828 | 0.78 | SLC6A2 (0.64) | HRH3CHRM2CHRM1CHRM3 | |
| SCHEMBL224219 | 0.78 | SLC6A2 (0.64) | HRH3CHRM2CHRM1CHRM3 | |
| SCHEMBL8434269 | 0.72 | HRH3 (0.58) | HRH3TRPC6 | |
| SCHEMBL29396616 | 0.72 | HRH3 (0.58) | HRH3TRPC6 | |
| SCHEMBL21130985 | 0.71 | HRH3 (0.67) | HRH3TRPC6 | |
| SCHEMBL4229898 | 0.71 | HRH3 (0.94) | HRH3 | |
| SCHEMBL28567321 | 0.69 | NPY1R (0.55) | HRH3TRPC6HRH2HRH1 | |
| SCHEMBL173113 | 0.69 | CHRM2 (0.61) | CHRM2CHRM4CHRM1CHRM3 | |
| Fumaric Acid SCHEMBL1178478 | 0.69 | SLC6A2 (0.55) | HRH3CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885TRPC6 453/4885CHRM2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.